|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CHRNB1 |
Gene summary for CHRNB1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CHRNB1 | Gene ID | 1140 |
| Gene name | cholinergic receptor nicotinic beta 1 subunit | |
| Gene Alias | ACHRB | |
| Cytomap | 17p13.1 | |
| Gene Type | protein-coding | GO ID | GO:0001941 | UniProtAcc | P11230 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 1140 | CHRNB1 | LZE4T | Human | Esophagus | ESCC | 1.03e-11 | 2.03e-01 | 0.0811 |
| 1140 | CHRNB1 | LZE24T | Human | Esophagus | ESCC | 7.26e-09 | 1.21e-01 | 0.0596 |
| 1140 | CHRNB1 | LZE6T | Human | Esophagus | ESCC | 5.21e-04 | 1.27e-01 | 0.0845 |
| 1140 | CHRNB1 | P1T-E | Human | Esophagus | ESCC | 2.81e-10 | 2.84e-01 | 0.0875 |
| 1140 | CHRNB1 | P2T-E | Human | Esophagus | ESCC | 6.53e-14 | 1.44e-01 | 0.1177 |
| 1140 | CHRNB1 | P4T-E | Human | Esophagus | ESCC | 4.30e-16 | 2.69e-01 | 0.1323 |
| 1140 | CHRNB1 | P5T-E | Human | Esophagus | ESCC | 9.34e-11 | 1.27e-01 | 0.1327 |
| 1140 | CHRNB1 | P8T-E | Human | Esophagus | ESCC | 7.48e-09 | 1.48e-01 | 0.0889 |
| 1140 | CHRNB1 | P9T-E | Human | Esophagus | ESCC | 2.24e-13 | 1.20e-01 | 0.1131 |
| 1140 | CHRNB1 | P10T-E | Human | Esophagus | ESCC | 3.06e-07 | 8.38e-02 | 0.116 |
| 1140 | CHRNB1 | P11T-E | Human | Esophagus | ESCC | 3.87e-10 | 3.07e-01 | 0.1426 |
| 1140 | CHRNB1 | P12T-E | Human | Esophagus | ESCC | 6.87e-16 | 1.29e-01 | 0.1122 |
| 1140 | CHRNB1 | P15T-E | Human | Esophagus | ESCC | 9.41e-05 | 6.43e-02 | 0.1149 |
| 1140 | CHRNB1 | P16T-E | Human | Esophagus | ESCC | 5.20e-15 | 2.73e-01 | 0.1153 |
| 1140 | CHRNB1 | P19T-E | Human | Esophagus | ESCC | 9.59e-03 | 4.62e-01 | 0.1662 |
| 1140 | CHRNB1 | P20T-E | Human | Esophagus | ESCC | 3.44e-19 | 2.21e-01 | 0.1124 |
| 1140 | CHRNB1 | P21T-E | Human | Esophagus | ESCC | 3.36e-17 | 2.23e-01 | 0.1617 |
| 1140 | CHRNB1 | P22T-E | Human | Esophagus | ESCC | 2.03e-18 | 3.11e-01 | 0.1236 |
| 1140 | CHRNB1 | P23T-E | Human | Esophagus | ESCC | 3.23e-17 | 2.48e-01 | 0.108 |
| 1140 | CHRNB1 | P24T-E | Human | Esophagus | ESCC | 1.42e-10 | 1.53e-01 | 0.1287 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00426927 | Oral cavity | OSCC | muscle cell differentiation | 175/7305 | 384/18723 | 4.79e-03 | 1.92e-02 | 175 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| SLURP1 | CHRNB1 | SLURP1_CHRNB1 | SLURP | Esophagus | ESCC |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CHRNB1 | SNV | Missense_Mutation | c.1274G>C | p.Arg425Pro | p.R425P | P11230 | protein_coding | tolerated(0.3) | benign(0.007) | TCGA-E9-A22D-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | SD | |
| CHRNB1 | insertion | Frame_Shift_Ins | novel | c.1292_1293insTGGCTGCATTTCCTTGTGTAGCTCGTTTGTGGAAGAATAT | p.Glu432GlyfsTer97 | p.E432Gfs*97 | P11230 | protein_coding | TCGA-B6-A0IA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| CHRNB1 | SNV | Missense_Mutation | novel | c.104N>G | p.Phe35Cys | p.F35C | P11230 | protein_coding | deleterious(0.02) | probably_damaging(1) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| CHRNB1 | SNV | Missense_Mutation | rs201453432 | c.512N>G | p.Ser171Cys | p.S171C | P11230 | protein_coding | deleterious(0) | probably_damaging(0.987) | TCGA-EK-A2PG-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
| CHRNB1 | SNV | Missense_Mutation | novel | c.891N>C | p.Lys297Asn | p.K297N | P11230 | protein_coding | deleterious(0.04) | possibly_damaging(0.526) | TCGA-VS-A950-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD |
| CHRNB1 | SNV | Missense_Mutation | c.295N>A | p.Asp99Asn | p.D99N | P11230 | protein_coding | tolerated(0.27) | benign(0.01) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| CHRNB1 | SNV | Missense_Mutation | c.1238N>T | p.Ala413Val | p.A413V | P11230 | protein_coding | tolerated(0.49) | benign(0.119) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
| CHRNB1 | SNV | Missense_Mutation | c.238N>T | p.Asp80Tyr | p.D80Y | P11230 | protein_coding | deleterious(0) | probably_damaging(0.933) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR | |
| CHRNB1 | SNV | Missense_Mutation | c.96G>T | p.Glu32Asp | p.E32D | P11230 | protein_coding | tolerated(0.31) | benign(0.009) | TCGA-CA-6718-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | PD | |
| CHRNB1 | SNV | Missense_Mutation | c.1215T>A | p.Asn405Lys | p.N405K | P11230 | protein_coding | deleterious(0.03) | benign(0.406) | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 1140 | CHRNB1 | DRUGGABLE GENOME, ION CHANNEL, TRANSPORTER | antagonist | CHEMBL1200993 | GALLAMINE TRIETHIODIDE | |
| 1140 | CHRNB1 | DRUGGABLE GENOME, ION CHANNEL, TRANSPORTER | antagonist | CHEMBL1200549 | RAPACURONIUM BROMIDE | |
| 1140 | CHRNB1 | DRUGGABLE GENOME, ION CHANNEL, TRANSPORTER | agonist | CHEMBL983 | SUCCINYLCHOLINE CHLORIDE | |
| 1140 | CHRNB1 | DRUGGABLE GENOME, ION CHANNEL, TRANSPORTER | antagonist | CHEMBL1237099 | DOXACURIUM CHLORIDE | |
| 1140 | CHRNB1 | DRUGGABLE GENOME, ION CHANNEL, TRANSPORTER | antagonist | CHEMBL1200641 | CISATRACURIUM BESYLATE | |
| 1140 | CHRNB1 | DRUGGABLE GENOME, ION CHANNEL, TRANSPORTER | antagonist | CHEMBL984 | MIVACURIUM CHLORIDE | |
| 1140 | CHRNB1 | DRUGGABLE GENOME, ION CHANNEL, TRANSPORTER | antagonist | CHEMBL1200722 | PIPECURONIUM BROMIDE | |
| 1140 | CHRNB1 | DRUGGABLE GENOME, ION CHANNEL, TRANSPORTER | antagonist | CHEMBL1200757 | PANCURONIUM BROMIDE | |
| 1140 | CHRNB1 | DRUGGABLE GENOME, ION CHANNEL, TRANSPORTER | antagonist | CHEMBL1739 | METOCURINE IODIDE | |
| 1140 | CHRNB1 | DRUGGABLE GENOME, ION CHANNEL, TRANSPORTER | antagonist | CHEMBL1200629 | VECURONIUM BROMIDE |
| Page: 1 2 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |